Dogwood Therapeutics Taps OrbiMed’s Iain Dukes as Scientific Advisory Chair
Event summary
- Dogwood Therapeutics appoints Iain Dukes, Ph.D., Venture Partner at OrbiMed, as Chair of its newly formed Scientific Advisory Board (SAB).
- Dukes brings extensive experience in ion channel therapeutics development, relevant to Dogwood’s Halneuron, a NaV 1.7 sodium channel inhibitor.
- Dogwood’s Phase 2b data for Halneuron in chemotherapy-induced neuropathic pain (CINP) is anticipated in fall 2026.
- SP16 IV, another pipeline candidate, has received FDA clearance to progress into Phase 1b development.
The big picture
Dogwood Therapeutics’ appointment of Iain Dukes underscores its focus on strengthening scientific governance amid a competitive landscape for non-opioid pain treatments. The move comes as the company prepares to release pivotal Phase 2b data for Halneuron, positioning itself in a market increasingly seeking alternatives to opioid-based therapies. Dukes’ extensive industry experience and connections could also open doors to strategic collaborations or funding opportunities.
What we're watching
- Clinical Trial Outcomes
- The anticipated Phase 2b data for Halneuron in fall 2026 will be critical in assessing its efficacy and potential market positioning.
- Strategic Advisory Impact
- Whether Dukes’ expertise can accelerate Dogwood’s pipeline development and attract further investment or partnerships.
- Regulatory Progress
- The pace at which SP16 IV advances through Phase 1b trials, given its FDA clearance and funding from the National Cancer Institute.
Related topics